| Term | Definition |
|---|---|
| NorPD | Norwegian Prescribed Drug Registry |
| Nosocomial | Hospital-acquired infection |
| NRL | National reference laboratory |
| NSAS | National Centre for Antibiotic Use in Hospitals |
| NTM | Non-tuberculosis mycobacterium |
| NVI | Norwegian Veterinary Institute |
| NWT | Non-wild type |
| OIE | World Organization for Animal Health, UN |
| OPAT | Outpatient parenteral antimicrobial therapy |
| PACT(A) | Prescribing analysis and cost (assessment) |
| PBP2 | Penicillin-binding protein 2 |
| PCU | Population correction unit |
| PIMs | Potentially Inappropriate Medications |
| PIP | Paediatric investigational plan |
| PJI | Prosthetic joint infection |
| PK | Pharmacokinetic |
| PMO | Program Management Office |
| PO | Oral |
| PPP | Public-private-partnership (in Danish: O-P-P) |
| PPS | Point prevalence survey |
| PTA | Probability of target attainment |
| QALY | Quality-adjusted life years: A measure used in health economics to assess the value of a medical intervention. It combines the length of life gained from a treatment with the quality of that life. A QALY is equal to one year of life in perfect health. The measure is often used to calculate a cost-per-QALY value, which helps policymakers and healthcare providers make decisions about the cost-effectiveness of different treatments. The monetary value of a QALY can vary widely depending on the country, time period, and the specific methodology used for its calculation. |
| QIDP | Qualified Infectious Disease Product |
| QRDR | Quinolone resistance-determining region |
| R&D | Research and development |
| rCDI | Recurrent Clostridium difficile infection |
| ReACT | Action on Antibiotic Resistance (Uppsala University, Sweden) |
| RR-TB | Rifampicin-resistant tuberculosis |
| RTO | Research & Technology Organization |
| Rx | Prescription |
| SaaS | Software as a Service (previously known as ASP, application service provider) |
| SACAR | Specialist Advisory Committee on Antimicrobial Resistance (UK, Dept. of Health) |
| SAD | Single ascending dose |
| SAE | Serious adverse event |
| SAP | Surgical antibiotic prophylaxis |
| SBL | Serine β-lactamase |
| SI | Selective index |
| SIRS | Systemic inflammatory response syndrome |
| SME | Small and medium-sized enterprise ( |
| SNOMED | Systematized Nomenclature of Medicine-Clinical Terms vs. DSM-IV and ICD-10. These are other standards for common language in medicine. The former, DSM-IV is American and stands for: Diagnostic and Statistic Manual version 4 and the latter is WHO’s system: International Classification of Diseases, version 10. |
| SOC | Standard of care |
| SSI | Surgical site infection |
| ST | Sequence type |
| STAAR | Strategies to Address Antimicrobial Resistance, US act introduced November 2007 |
| TB | Tuberculosis |
| TEAE | Treatment emergent adverse events |
| TOC | Test-of-cure |
| TRL | Technology Readiness Level, term and system developed to guide on a product or service’s go-to-market maturity |
| TTO | Technology Transfer Office, entity at university dedicated to bringing academic inventions to use by industry and society |
| TTP | Time to positivity |